Biogen Launches $41/Share Tender Offer for Apellis Pharmaceuticals (APLS)
Biogen is acquiring Apellis Pharmaceuticals (APLS) for $41/share cash plus a CVR worth up to $4/share. APLS trades at $40.70 with a 0.7% spread. All-cash, no financing contingency, expected Q2 2026 close.
- Biogen (BIIB) is acquiring Apellis Pharmaceuticals (NASDAQ: APLS) for $41.00 per share in cash plus a non-transferable CVR worth up to $4.00 per share. Total upfront deal value is approximately $5.6 billion.
- APLS trades at $40.70, leaving a razor-thin 0.7% spread to the cash offer. The market is treating this as a near-certainty to close.
- The CVR is tied to SYFOVRE hitting $1.5B or $2.0B in annual global sales by 2030-2031. SYFOVRE did $587M in 2025 (and declined 4% year-over-year), so the CVR milestones require roughly a 3x revenue increase — a long shot.
- This is an all-cash deal with no financing contingency, supported by tender agreements covering ~14% of shares. HSR clearance is the main hurdle. Expected close in Q2 2026.
The Offer
Biogen Inc. (NASDAQ: BIIB), through its subsidiary Aspen Purchaser Sub, is launching a tender offer for all outstanding shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) at $41.00 per share in cash, plus one non-transferable contingent value right (CVR) per share. The Merger Agreement was signed on March 31, 2026, and the deal is structured as a tender offer followed by a Section 251(h) back-end merger — no shareholder vote required once a majority of shares are tendered.
Apellis is a commercial-stage biotech focused on complement-targeted therapies, with two approved drugs generating about $689 million in combined 2025 net sales. The $41.00 offer price represents a 140% premium to APLS's $17.10 closing price on March 30, the last trading day before the announcement, and a 35% premium to the 52-week high of $30.37. Both boards approved the transaction. Biogen is financing the deal with a combination of cash on hand and borrowings, with no financing contingency.
Why This Is Interesting
The short answer: it probably isn't, unless you are already holding APLS shares. At $40.70, the stock trades just $0.30 below the $41.00 cash offer — a spread of 0.7%. For a deal expected to close in Q2 2026, that annualized return is minimal. The arb community has already priced this as a done deal, and for good reason: it is all-cash with no financing contingency, insider support agreements lock up ~14% of shares, and the only meaningful regulatory gate is HSR clearance for a pharma-on-pharma acquisition that raises no obvious antitrust concerns.
The more interesting question is what to do about the CVR. Each share comes with a non-transferable CVR that could pay up to $4.00 in additional cash. But since you cannot sell the CVR — it is locked to your account after closing — you need to assess whether those milestones are realistic before deciding to hold through closing versus selling in the open market at $40.70 today. More on that below.
The CVR: Worth $4 or Worth Nothing
Each CVR entitles the holder to cash payments based on SYFOVRE's annual global net sales:
| Milestone | CVR Payment | Measurement Period |
|---|---|---|
| SYFOVRE hits $1.5B annual global net sales | $2.00 per share | Any calendar year 2027-2030 |
| SYFOVRE hits $2.0B annual global net sales | Additional $2.00 per share | Any calendar year 2027-2030 |
| If neither threshold met in 2027-2030, but $2.0B hit in 2031 | $4.00 per share | Calendar year 2031 only |
Here is the reality check. SYFOVRE generated $587 million in 2025 net sales, which was actually a 4% decline from 2024. Hitting $1.5 billion requires roughly tripling revenue within four years. Biogen's press release projects "mid-to-high teens" growth for the combined Apellis portfolio through 2028, but even 20% annual growth from SYFOVRE's 2025 base only gets you to about $1.2 billion by 2030 — still short of the first milestone. The $2 billion threshold is even more remote.
The CVRs are non-transferable, so there is no secondary market to exit. If you tender your shares and receive CVRs, you are locked in for years with no liquidity and a low-probability payout. For most investors, the CVR is a free lottery ticket — nice to have, but not something to factor heavily into your decision-making.
Key Terms
- Minimum tender condition: Majority of outstanding shares (approximately 127.9 million shares total as of March 31, 2026). With ~14% already committed via support agreements from insiders and Morningside Venture Investments, the bar is achievable.
- Financing: All-cash, no financing contingency. Biogen is using a combination of cash on hand and borrowings, and expects to fully de-lever by end of 2027.
- Regulatory approvals: HSR Act antitrust clearance required. Both parties committed to filing within 15 business days of the Merger Agreement (by approximately April 22, 2026). No other regulatory hurdles have been disclosed.
- Termination fee: $205 million payable by Apellis to Biogen if Apellis accepts a superior proposal or changes its board recommendation.
- Merger structure: Section 251(h) short-form merger following successful tender. No separate shareholder vote needed.
- Tender offer period: 20 business days from commencement. The formal offer has not yet commenced — only pre-commencement communications have been filed.
Timeline
Merger Agreement signed between Biogen, Aspen Purchaser Sub, and Apellis. Support agreements executed by holders of ~14% of shares.
SC TO-C pre-commencement communication filed by Biogen.
SC 14D-9C preliminary communication filed by Apellis (employee FAQ).
HSR Act filing deadline (15 business days from Merger Agreement).
Formal tender offer commencement (Schedule TO filing). The offer will remain open for at least 20 business days.
Offer expiration, closing, and Section 251(h) back-end merger. APLS will be delisted and become a wholly owned Biogen subsidiary.
Risks
- HSR/antitrust risk is low. Both companies operate in the pharmaceutical space, but Apellis's complement-targeted therapies do not directly overlap with Biogen's existing portfolio. This is a portfolio-expansion deal, not a market-consolidation play. Clearance should be straightforward.
- Deal break risk exists but is remote. The $205 million termination fee raises the bar for a competing bid. At $41.00 plus CVRs, Apellis is already valued well above where any analyst had it pre-deal (consensus target was ~$33). A topping bid would need to exceed $41.00 in cash, and no competing interest has surfaced.
- The spread offers almost no return. At $40.70, you are picking up $0.30 per share (0.7%) for a deal expected to close in a few months. After transaction costs, this is not a compelling arb entry. The risk/reward makes sense only if you already own shares.
- CVR value is speculative. SYFOVRE's sales trajectory does not currently support reaching $1.5 billion by 2030. If the drug does not achieve a major inflection — whether through label expansion, international launches, or market share gains — CVR holders receive nothing. And since CVRs are non-transferable, you cannot exit the position.
- Pre-commencement stage. The formal tender offer has not launched. Until Biogen files the Schedule TO, we do not have the complete offer terms, including any odd-lot provisions that may or may not be included. Material terms could still shift before commencement.
Tax Treatment
This is a straightforward all-cash acquisition of a U.S. domestic company by another U.S. company. For U.S. taxpayers, tendering shares for $41.00 cash will generally be treated as a taxable sale, with gain or loss measured against your cost basis. The CVR adds a wrinkle: the IRS may treat the CVR as part of the total consideration received at closing, requiring you to allocate basis between the cash and CVR components. The formal tender offer documents (when filed) should include a section on tax treatment with more specifics. Consult a tax advisor if you hold a significant position.
This analysis is for informational purposes only and does not constitute investment advice. Read the complete filing and consult your own advisors before making any decisions.